Search Results - "RUDICK, R. A"

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis by O'CONNOR, P. W, GOODMAN, A, KAPPOS, L, LUBLIN, F. D, MILLER, D. H, POLMAN, C, RUDICK, R. A, ASCHENBACH, W, LUCAS, N

“…Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment of…”
Get full text

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures by Ontaneda, D, LaRocca, N, Coetzee, T, Rudick, RA

“…This article describes proceedings from a meeting of the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures (the TF). The TF…”
Get full text

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire by Benedict, RHB, Duquin, JA, Jurgensen, S, Rudick, RA, Feitcher, J, Munschauer, FE, Panzara, MA, Weinstock-Guttman, B

“…Background Brief cognitive performance tests and self-report measures of neuropsychological symptoms have been proposed for screening purposes in multiple…”
Get full text

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment by Fischer, J S, Rudick, R A, Cutter, G R, Reingold, S C

“…Clinical outcome assessment in Multiple Sclerosis (MS) is challenging due to the diversity and fluctuating nature of MS symptoms. Traditional clinical scales…”
Get full text

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks by Morrow, SA, O'Connor, PW, Polman, CH, Goodman, AD, Kappos, L, Lublin, FD, Rudick, RA, Jurgensen, S, Paes, D, Forrestal, F, Benedict, RHB

“…Background and Objectives: Brief cognitive tests to monitor cognitive impairment in patients with multiple sclerosis (MS) are needed. Methods: Performance on…”
Get full text

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS by ZIVADINOV, R, RUDICK, R. A, DE MASI, R, NASUELLI, D, UKMAR, M, POZZI-MUCELLI, R. S, GROP, A, CAZZATO, G, ZORZON, M

“…IV methylprednisolone (IVMP) has been used to treat relapses in patients with relapsing-remitting (RR) MS, but its effect on disease progression is not known…”
Get full text

Eight-year follow-up study of brain atrophy in patients with MS by FISHER, E, RUDICK, R. A, SIMONIAN, N. A, SIMON, J. H, CUTTER, G, BAIER, M, LEE, J.-C, MILLER, D, WEINSTOCK-GUTTMAN, B, MASS, M. K, DOUGHERTY, D. S

“…To characterize whole-brain atrophy in relapsing-remitting MS (RRMS) patients over an 8-year period. The specific goals of this study were to determine if…”
Get full text

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis by BAIER, M. L, CUTTER, G. R, RUDICK, R. A, MILLER, D, COHEN, J. A, WEINSTOCK-GUTTMAN, B, MASS, M, BALCER, L. J

“…To evaluate concurrent and predictive validity for low-contrast letter acuity (L-CLA) testing as a candidate visual component for the Multiple Sclerosis…”
Get full text

Axonal loss in normal-appearing white matter in a patient with acute MS by BJARTMAR, C, KINKEL, R. P, KIDD, G, RUDICK, R. A, TRAPP, B. D

“…Brain imaging studies detect abnormalities in normal-appearing white matter in patients with MS. To investigate the histopathologic basis for these changes in…”
Get full text

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis by Fisher, E, Nakamura, K, Lee, J-C, You, X, Sperling, B, Rudick, RA

“…Background: Changes in gray matter (GM) volume may be a useful measure of tissue loss in multiple sclerosis (MS). Objectives: To investigate the rate,…”
Get full text

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials by Rudick, R A, Cutter, G, Reingold, S

“…With the advent and widespread use of partially effective disease modifying drug therapies for multiple sclerosis (MS), future clinical trials will undoubtedly…”
Get full text

Assessing disability progression with the Multiple Sclerosis Functional Composite by Rudick, RA, Polman, CH, Cohen, JA, Walton, MK, Miller, AE, Confavreux, C, Lublin, FD, Hutchinson, M, O’Connor, PW, Schwid, SR, Balcer, LJ, Lynn, F, Panzara, MA, Sandrock, AW

“…Background The initial Multiple Sclerosis Functional Composite (MSFC) proposal was a three-part composite of quantitative measures of ambulation, upper…”
Get full text

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis by BALCER, L. J, GALETTA, S. L, O'CONNOR, P. W, PHILLIPS, J. T, POLMAN, C. H, RADUE, E.-W, RUDICK, R. A, STUART, W. H, WAJGT, A, WEINSTOCK-GUTTMAN, B, WYNN, D. R, LYNN, F, CALABRESI, P. A, PANZARA, M. A, CONFAVREUX, C, GIOVANNONI, G, HAVRDOVA, E, HUTCHINSON, M, KAPPOS, L, LUBLIN, F. D, MILLER, D. H

“…To examine the effects of natalizumab on low-contrast letter acuity as a prespecified tertiary endpoint in two randomized clinical trials and to evaluate the…”
Get full text

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a by RUDICK, R. A, PACE, A, GALETTA, S. L, LUBLIN, F. D, RADUE, E.-W, RANSOHOFF, R. M, RANI, M. R. S, HYDE, R, PANZARA, M, APPACHI, S, SHROCK, J, MAURER, S. L, CALABRESI, P. A, CONFAVREUX, C

“…Findings from a small clinical study suggested that statins may counteract the therapeutic effects of interferon beta (IFNbeta) in patients with…”
Get full text

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study by Bermel, RA, Weinstock-Guttman, B., Bourdette, D., Foulds, P., You, X., Rudick, RA

“…Disease-modifying drugs are initiated early and continued for years in patients with multiple sclerosis. Long-term tolerability and impact are not known. The…”
Get full text

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS by RUDICK, R. A, FISHER, E, LEE, J.-C, SIMON, J, JACOBS, L

Get full text

T‐cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking by KIVISÄKK, P., TREBST, C., LIU, Z., TUCKY, B. H., SØRENSEN, T. L., RUDICK, R. A., MACK, M., RANSOHOFF, R. M.

“…SUMMARY It is believed that chemokines and their receptors are involved in trafficking of T‐cells to the central nervous system (CNS). The aim of the current…”
Get full text

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis by RUDICK, R. A, RANSOHOFF, R. M, LEE, J.-C, PEPPLER, R, YU, M, MATHISEN, P. M, TUOHY, V. K

“…Recombinant interferon beta (IFNbeta) benefits patients with relapsing remitting multiple sclerosis (MS), but the mechanisms of action are unknown. We studied…”
Get full text

Use of the multiple sclerosis Functional Composite to predict disability in relapsing MS by RUDICK, R. A, CUTTER, G, BAIER, M, FISHER, E, DOUGHERTY, D, WEINSTOCK-GUTTMAN, B, MASS, M. K, MILLER, D, SIMONIAN, N. A

“…To determine whether the MS Functional Composite (MSFC) can predict future disease progression in patients with relapsing remitting MS (RR-MS). The MSFC was…”
Get full text

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis by RUDICK, R. A, SIMONIAN, N. A, MASS, M. K, RICHERT, J. R, SALAZAR, A. M, MUNSCHBAUER, F. E, COOKFAIR, D. L, SIMON, J. H, JACOBS, L. D, ALAM, J. A, CAMPION, M, SCARAMUCCI, J. O, JONES, W, COATS, M. E, GOODKIN, D. E, WEINSTOCK-GUTTMAN, B, HERNDON, R. M

Get full text